Cardiac and haemodynamic effects of tacrolimus in the halothane- anaesthetized dog

Basic and Clinical Pharmacology and Toxicology

Volumn 106, Issue 4, 2010, Pages 288-295

  Kise, Hiroaki ^a   Nakamura, Yuji ^a   Hoshiai, Minako ^a   Sugiyama, Hisashi ^a   Sugita, Kanji ^a   Sugiyama, Atsushi ^a,b  

^a UNIVERSITY OF YAMANASHI   (Japan)

^b Yamanashi Research Center of Clinical Pharmacology   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; HALOTHANE; HEPARIN CALCIUM; ION CHANNEL; POTASSIUM CHANNEL HERG; TACROLIMUS;

ANIMAL EXPERIMENT; ARTICLE; BLOOD PRESSURE; CARDIOPULMONARY HEMODYNAMICS; CARDIOTOXICITY; CARDIOVASCULAR EFFECT; CHRONOTROPISM; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG INFUSION; DRUG MEGADOSE; DRUG MONITORING; DRUG WITHDRAWAL; ELECTRIC ACTIVITY; EMBRYO; EMBRYO CELL; FEMALE; HEART ELECTROPHYSIOLOGY; HEART REPOLARIZATION; HUMAN; HUMAN CELL; INOTROPISM; KIDNEY CELL; LOW DRUG DOSE; MALE; NONHUMAN; POTASSIUM CURRENT; PRIORITY JOURNAL;

ANESTHETICS, INHALATION; ANIMALS; BLOOD PRESSURE; CELL LINE; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; ELECTROPHYSIOLOGY; ETHER-A-GO-GO POTASSIUM CHANNELS; FEMALE; HALOTHANE; HEMODYNAMICS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; MALE; TACROLIMUS;

CANIS FAMILIARIS;

EID: 77949429768     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2009.00477.x     Document Type: Article

References (36)

1. Kino T, Hatanaka H, Hashimoto M, Nishiyama M, Goto T, Okuhara M et al. FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physicochemical and biological characteristics. J Antibiot 1987;40: 1249-55.
2. Kino T, Hatanaka H, Miyata S, Inamura N, Nishiyama M, Yajima T et al. FK-506, a novel immunosuppressant isolated from a Streptomyces. II: immunosuppressive effect of FK-506 in vitro. J Antibiot 1987;40:1256-65.
3. Krensky AM, Vincenti F, Bennett WM. Immunomodulators: immunosuppressants, tolerogens, and immunostimulants. In: Brunton LL (ed.). Goodman & Gilman's The Pharmacological Basis of Therapeutics, 11th edn. McGraw-Hill, New York, 2005;1405-31.
4. Furuichi Y, Maeda M, Moriguchi A, Sawamoto T, Kawamura A, Matsuoka N et al. Tacrolimus, a potential neuroprotective agent, ameliorates ischemic brain damage and neurologic deficits after focal cerebral ischemia in nonhuman primates. J Cereb Blood Flow Metab 2003;23:1183-94.
5. Furuichi Y, Noto T, Li JY, Oku T, Ishiye M, Moriguchi A et al. Multiple modes of action of tacrolimus (FK506) for neuroprotective action on ischemic damage after transient focal cerebral ischemia in rats. Brain Res 2004;1014:120-30.
6. Maeda M, Furuichi Y, Ueyama N, Moriguchi A, Satoh N, Matsuoka N et al. A combined treatment with tacrolimus (FK506) and recombinant tissue plasminogen activator for thrombotic focal cerebral ischemia in rats: increased neuroprotective efficacy and extended therapeutic time window. J Cereb Blood Flow Metab 2003;10:1205-11.
7. Shichinohe H, Kuroda S, Abumiya T, Ikeda J, Kobayashi T, Yoshimoto T et al. FK506 reduces infarct volume due to permanent focal cerebral ischemia by maintaining BAD turnover and inhibiting cytochrome c release. Brain Res 2004;1001:51-9.
8. Squadrito F, Altavilla D, Squadrito G, Saitta A, Deodato B, Arlotta M et al. Tacrolimus limits polymorphonuclear leucocyte accumulation and protects against myocardial ischaemia-reperfusion injury. J Mol Cell Cardiol 2000;32:429-40.
9. Weinbrenner C, Liu GS, Downey JM, Cohen MV. Cyclosporine A limits myocardial infarct size even when administered after onset of ischemia. Cardiovasc Res 1998;38:678-84.
10. Calandra S. Sinus arrest during tacrolimus treatment: was the QT interval prolonged? Transplantation 1998;66:402-4.
11. Gerhardt U, Suwelack B, Pawolka A, Hohage H. High QT dispersion in tacrolimus-treated kidney transplant recipients. Transplant Proc 2001;33:2148-50.
12. Hodak SP, Moubarak JB, Rodriguez I, Gelfand MC, Alijani MR, Tracy CM. QT prolongation and near fatal cardiac arrhythmia after intravenous tacrolimus administration: a case report. Transplantation 1998;66:535-7.
13. Johnson MC, So S, Marsh JW, Murphy AM. QT prolongation and torsades de pointes after administration of FK506. Transplantation 1992;53:929-30.
14. Nishimura M, Kim K, Uchiyama A, Fujino Y, Nishimura S, Taenaka N et al. Tacrolimus-induced life-threatening arrhythmia in a pediatric liver-transplant patient. Intensive Care Med 2002;28:1683-4.
15. Minematsu T, Ohtani H, Sato H, Iga T. Sustained QT prolongation induced by tacrolimus in guinea pigs. Life Sci 1999;65:PL197-202.
16. Minematsu T, Ohtani H, Sato H, Iga T. Pharmacokinetic/pharmacodynamic analysis of tacrolimus-induced QT prolongation in guinea pigs. Biol Pharm Bull 1999;22:1341-6.
17. Ozkanlar Y, Nishijima Y, da Cunha D, Hamlin RL. Acute effects of tacrolimus (FK506) on left ventricular mechanics. Pharmacol Res 2005;52:307-12.
18. Sugiyama A. Sensitive and reliable proarrhythmia in vivo animal models for predicting drug-induced torsades de pointes in patients with remodelled hearts. Br J Pharmacol 2008;154:1528-37.
19. Kr channel blocker sematilide on the relationship between ventricular repolarization, refractoriness and onset of torsades de pointes. Jpn J Pharmacol 2002;88:414-21.
20. Van de Water A, Verheyen J, Xhonneux R, Reneman RS. An improved method to correct the QT interval of the electrocardiogram for changes in heart rate. J Pharmacol Methods 1989;22:207-17.
21. Soydan G, Tekes E, Tuncer M. Short-term and long-term FK506 treatment alters the vascular reactivity of renal and mesenteric vascular beds. J Pharmacol Sci 2006;102:359-67.
22. Takeda Y, Miyamori I, Furukawa K, Inaba S, Mabuchi H. Mechanisms of FK 506-induced hypertension in the rat. Hypertension 1999;33:130-6.
23. Long C, Cook LG, Wu GY, Mitchell BM. Removal of Fkbp12/12.6 from endothelial ryanodine receptors leads to an intracellular calcium leak and endothelial dysfunction. Arterioscler Thromb Vasc Biol 2007;27:1580-6.
24. Margreiter R. Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: a randomised multicentre study. Lancet 2002;359:741-6.
25. The U.S. Multicenter FK506 Liver Study Group. A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med 1994;331:1110-5.
26. 2+ channels by FK506 in porcine coronary artery. Br J Pharmacol 1999;126:717-29.
27. 2+ transients in rat cardiac myocytes. Circ Res 1996;79:1110-21.
28. Cox TH, Baillie GM, Baliga P. Bradycardia associated with intravenous administration of tacrolimus in a liver transplant recipient. Pharmacotherapy 1997;17:1328-30.
29. Fauconnier J, Lacampagne A, Rauzier JM, Fontanaud P, Frapier JM, Sejersted OM et al. Frequency-dependent and proarrhythmogenic effects of FK-506 in rat ventricular cells. Am J Physiol Heart Circ Physiol 2005;288:H778-86.
30. Sugiyama A, Motomura S, Hashimoto K. Utilization of an isolated, blood-perfused canine papillary muscle preparation as a model to assess efficacy and adversity of class I antiarrhythmic drugs. Jpn J Pharmacol 1994;66:303-16.
31. Minematsu T, Ohtani H, Yamada Y, Sawada Y, Sato H, Iga T. Quantitative relationship between myocardial concentration of tacrolimus and QT prolongation in guinea pigs: pharmacokinetic/pharmacodynamic model incorporating a site of adverse effect. J Pharmacokinet Pharmacodyn 2001;28:533-54.
32. + currents in rat ventricular myocytes. J Physiol 1997;501:509-16.
33. + currents by the immunosuppressant FK-506 in rat ventricle. Am J Physiol 1998;275:H2041-52.
34. + currents responsible for repolarization in mouse ventricle and their modulation by FK-506 and rapamycin. Am J Physiol Heart Circ Physiol 2000;278:H886-97.
35. Yokoyama H, Nakamura Y, Iwasaki H, Nagayama Y, Hoshiai Y, Mitsumori Y et al. Effects of acute intravenous administration of pentamidine, a typical hERG trafficking inhibitor, on the cardiac repolarization process of the halothane-anesthetized dogs. J Pharmacol Sci 2009;110:476-82.
36. Van der Heyden MAG, Smits ME, Vos MA. Drugs and trafficking of ion channels: a new pro-arrhythmic threat on the horizon?. Br J Pharmacol 2008;153:406-9.